{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:24:57Z","timestamp":1776119097825,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T00:00:00Z","timestamp":1449705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/hr.2015.141","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T07:16:05Z","timestamp":1449731765000},"page":"237-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure"],"prefix":"10.1038","volume":"39","author":[{"given":"Ryo","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Wakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,10]]},"reference":[{"key":"BFhr2015141_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296\u20131305.","journal-title":"N Engl J Med"},{"key":"BFhr2015141_CR2","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1161\/CIRCULATIONAHA.109.886473","volume":"121","author":"JS Bock","year":"2010","unstructured":"Bock JS, Gottlieb SS . Cardiorenal syndrome: new perspectives. Circulation 2010; 121: 2592\u20132600.","journal-title":"Circulation"},{"key":"BFhr2015141_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.ajkd.2010.04.012","volume":"56","author":"AA House","year":"2010","unstructured":"House AA, Haapio M, Lassus J, Bellomo R, Ronco C . Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis 2010; 56: 759\u2013773.","journal-title":"Am J Kidney Dis"},{"key":"BFhr2015141_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/eurheartj\/ehi020","volume":"26","author":"LG Bongartz","year":"2005","unstructured":"Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B . The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26: 11\u201317.","journal-title":"Eur Heart J"},{"key":"BFhr2015141_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1161\/CIRCRESAHA.110.226803","volume":"108","author":"JG Dickhout","year":"2011","unstructured":"Dickhout JG, Carlisle RE, Austin RC . Interrelationship between cardiac hypertrophy, heart failure, and chronic kidney disease: endoplasmic reticulum stress as a mediator of pathogenesis. Circ Res 2011; 108: 629\u2013642.","journal-title":"Circ Res"},{"key":"BFhr2015141_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000313363","volume":"31","author":"HM Siragy","year":"2010","unstructured":"Siragy HM, Carey RM . Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010; 31: 541\u2013550.","journal-title":"Am J Nephrol"},{"key":"BFhr2015141_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.yjmcc.2009.08.002","volume":"48","author":"Y Sun","year":"2010","unstructured":"Sun Y . Intracardiac renin-angiotensin system and myocardial repair\/remodeling following infarction. J Mol Cell Cardiol 2010; 48: 483\u2013489.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr2015141_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0031-6997(24)01434-0","volume":"52","author":"S Kim","year":"2000","unstructured":"Kim S, Iwao H . Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11\u201334.","journal-title":"Pharmacol Rev"},{"key":"BFhr2015141_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/hr.2013.119","volume":"37","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Shao L, Ma A, Guan G, Wang J, Wang Y, Tian G . Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-beta1\/Smad signal pathway. Hypertens Res 2014; 37: 43\u201349.","journal-title":"Hypertens Res"},{"key":"BFhr2015141_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/hr.2012.223","volume":"36","author":"FA Zouein","year":"2013","unstructured":"Zouein FA, Zgheib C, Hamza S, Fuseler JW, Hall JE, Soljancic A, Lopez-Ruiz A, Kurdi M, Booz GW . Role of stat3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking stat3 serine 727 phosphorylation. Hypertens Res 2013; 36: 496\u2013503.","journal-title":"Hypertens Res"},{"key":"BFhr2015141_CR11","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/cvr\/cvn333","volume":"81","author":"Y Sun","year":"2009","unstructured":"Sun Y . Myocardial repair\/remodelling following infarction: roles of local factors. Cardiovasc Res 2009; 81: 482\u2013490.","journal-title":"Cardiovasc Res"},{"key":"BFhr2015141_CR12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/labinvest.2011.45","volume":"91","author":"Y Maejima","year":"2011","unstructured":"Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, Isobe M . Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating ppar gamma. Lab Invest 2011; 91: 932\u2013944.","journal-title":"Lab Invest"},{"key":"BFhr2015141_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/hr.2014.136","volume":"38","author":"K Nagasawa","year":"2015","unstructured":"Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T, Nagata K . Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertens Res 2015; 38: 39\u201347.","journal-title":"Hypertens Res"},{"key":"BFhr2015141_CR14","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/labinvest.2012.136","volume":"92","author":"M Ogawa","year":"2012","unstructured":"Ogawa M, Suzuki J, Takayama K, Senbonmatsu T, Hirata Y, Nagai R, Isobe M . Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release. Lab Invest 2012; 92: 1766\u20131776.","journal-title":"Lab Invest"},{"key":"BFhr2015141_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851\u2013860.","journal-title":"N Engl J Med"},{"key":"BFhr2015141_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/107424840300800307","volume":"8","author":"BI Jugdutt","year":"2003","unstructured":"Jugdutt BI, Menon V . Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat. J Cardiovasc Pharmacol Ther 2003; 8: 217\u2013226.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"BFhr2015141_CR17","doi-asserted-by":"publisher","first-page":"R815","DOI":"10.1152\/ajpregu.00727.2009","volume":"298","author":"LG Bongartz","year":"2010","unstructured":"Bongartz LG, Braam B, Verhaar MC, Cramer MJ, Goldschmeding R, Gaillard CA, Doevendans PA, Joles JA . Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 2010; 298: R815\u2013R823.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"BFhr2015141_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1590\/S0102-86502006000400012","volume":"21","author":"LS Santos","year":"2006","unstructured":"Santos LS, Chin EW, Ioshii SO, Tambara Filho R . Surgical reduction of the renal mass in rats: morphologic and functional analysis on the remnant kidney. Acta Cir Bras 2006; 21: 252\u2013257.","journal-title":"Acta Cir Bras"},{"key":"BFhr2015141_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejphar.2004.04.046","volume":"494","author":"Y Okada","year":"2004","unstructured":"Okada Y, Nakata M, Izumoto H, Takasu M, Tazawa N, Takaoka M, Gariepy CE, Yanagisawa M, Matsumura Y . Role of endothelin ETB receptor in partial ablation-induced chronic renal failure in rats. Eur J Pharmacol 2004; 494: 63\u201371.","journal-title":"Eur J Pharmacol"},{"key":"BFhr2015141_CR20","doi-asserted-by":"publisher","first-page":"H530","DOI":"10.1152\/ajpheart.00549.2006","volume":"292","author":"Y Onai","year":"2007","unstructured":"Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, Isobe M . Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 2007; 292: H530\u2013H538.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFhr2015141_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbrc.2011.04.142","volume":"409","author":"K Tsukuda","year":"2011","unstructured":"Tsukuda K, Mogi M, Iwanami J, Min LJ, Jing F, Oshima K, Horiuchi M . Irbesartan attenuates ischemic brain damage by inhibition of MCP-1\/CCR2 signaling pathway beyond AT(1) receptor blockade. Biochem Biophys Res Commun 2011; 409: 275\u2013279.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFhr2015141_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1254\/fpj.133.275","volume":"133","author":"Y Ariyoshi","year":"2009","unstructured":"Ariyoshi Y, Mizumoto K . Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan. Nihon Yakurigaku Zasshi 2009; 133: 275\u2013280.","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"BFhr2015141_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejheart.2006.05.007","volume":"9","author":"J Suzuki","year":"2007","unstructured":"Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Sagesaka YM, Isobe M . Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007; 9: 152\u2013159.","journal-title":"Eur J Heart Fail"},{"key":"BFhr2015141_CR24","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1016\/j.lfs.2004.11.028","volume":"76","author":"RS Smith Jr","year":"2005","unstructured":"Smith RS Jr, Agata J, Xia CF, Chao L, Chao J . Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 2005; 76: 2457\u20132471.","journal-title":"Life Sci"},{"key":"BFhr2015141_CR25","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1253\/circj.CJ-11-1114","volume":"76","author":"Y Kameda","year":"2012","unstructured":"Kameda Y, Hasegawa H, Kubota A, Tadokoro H, Kobayashi Y, Komuro I, Takano H . Effects of pitavastatin on pressure overload-induced heart failure in mice. Circ J 2012; 76: 1159\u20131168.","journal-title":"Circ J"},{"key":"BFhr2015141_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.yjmcc.2006.10.006","volume":"42","author":"J Suzuki","year":"2007","unstructured":"Suzuki J, Ogawa M, Maejima Y, Isobe K, Tanaka H, Sagesaka YM, Isobe M . Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. J Mol Cell Cardiol 2007; 42: 432\u2013440.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr2015141_CR27","doi-asserted-by":"publisher","first-page":"e82201","DOI":"10.1371\/journal.pone.0082201","volume":"8","author":"SW Tsang","year":"2013","unstructured":"Tsang SW, Zhang H, Lin C, Xiao H, Wong M, Shang H, Yang ZJ, Lu A, Yung KK, Bian Z . Rhein, a natural anthraquinone derivative, attenuates the activation of pancreatic stellate cells and ameliorates pancreatic fibrosis in mice with experimental chronic pancreatitis. PLoS ONE 2013; 8: e82201.","journal-title":"PLoS ONE"},{"key":"BFhr2015141_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/ki.2011.403","volume":"81","author":"K Sonomura","year":"2012","unstructured":"Sonomura K, Okigaki M, Kimura T, Matsuoka E, Shiotsu Y, Adachi T, Kado H, Ishida R, Kusaba T, Matsubara H, Mori Y . The kinase Pyk2 is involved in renal fibrosis by means of mechanical stretch-induced growth factor expression in renal tubules. Kidney Int 2012; 81: 449\u2013457.","journal-title":"Kidney Int"},{"key":"BFhr2015141_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.yjmcc.2013.09.015","volume":"65","author":"JM Siddesha","year":"2013","unstructured":"Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B . Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and reck. J Mol Cell Cardiol 2013; 65: 9\u201318.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr2015141_CR30","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.cellsig.2014.06.011","volume":"26","author":"P Balakumar","year":"2014","unstructured":"Balakumar P, Jagadeesh G . A century old renin-angiotensin system still grows with endless possibilities: At1 receptor signaling cascades in cardiovascular physiopathology. Cell Signal 2014; 26: 2147\u20132160.","journal-title":"Cell Signal"},{"key":"BFhr2015141_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00395-011-0242-4","volume":"107","author":"MK Szymanski","year":"2012","unstructured":"Szymanski MK, Buikema JH, van Veldhuisen DJ, Koster J, van der Velden J, Hamdani N, Hillege JL, Schoemaker RG . Increased cardiovascular risk in rats with primary renal dysfunction; mediating role for vascular endothelial function. Basic Res Cardiol 2012; 107: 242.","journal-title":"Basic Res Cardiol"},{"key":"BFhr2015141_CR32","doi-asserted-by":"publisher","first-page":"F1253","DOI":"10.1152\/ajprenal.00392.2012","volume":"303","author":"LG Bongartz","year":"2012","unstructured":"Bongartz LG, Braam B, Gaillard CA, Cramer MJ, Goldschmeding R, Verhaar MC, Doevendans PA, Joles JA . Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 2012; 303: F1253\u2013F1263.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFhr2015141_CR33","doi-asserted-by":"publisher","first-page":"30a","DOI":"10.1016\/j.amjcard.2009.10.009","volume":"105","author":"BJ Hoogwerf","year":"2010","unstructured":"Hoogwerf BJ . Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105: 30a\u201335a.","journal-title":"Am J Cardiol"},{"issue":"Pt 2","key":"BFhr2015141_CR34","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.clinthera.2008.12.002","volume":"30","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG . Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. Clin Ther 2008; 30 (Pt 2): 2181\u20132190.","journal-title":"Clin Ther"},{"key":"BFhr2015141_CR35","doi-asserted-by":"publisher","first-page":"311s","DOI":"10.1016\/S0895-7061(97)00391-9","volume":"10","author":"HR Brunner","year":"1997","unstructured":"Brunner HR . The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10: 311s\u2013317s.","journal-title":"Am J Hypertens"},{"key":"BFhr2015141_CR36","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/hr.2010.135","volume":"33","author":"M Fujino","year":"2010","unstructured":"Fujino M, Miura S, Kiya Y, Tominaga Y, Matsuo Y, Karnik SS, Saku K . A small difference in the molecular structure of angiotensin II receptor blockers induces at(1) receptor-dependent and -independent beneficial effects. Hypertens Res 2010; 33: 1044\u20131052.","journal-title":"Hypertens Res"},{"key":"BFhr2015141_CR37","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1517\/14656560903103820","volume":"10","author":"P Bramlage","year":"2009","unstructured":"Bramlage P, Durand-Zaleski I, Desai N, Pirk O, Hacker C . The value of irbesartan in the management of hypertension. Expert Opin Pharmacother 2009; 10: 1817\u20131831.","journal-title":"Expert Opin Pharmacother"},{"key":"BFhr2015141_CR38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2165\/00003495-200464090-00011","volume":"64","author":"KF Croom","year":"2004","unstructured":"Croom KF, Curran MP, Goa KL, Perry CM . Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999\u20131028.","journal-title":"Drugs"},{"key":"BFhr2015141_CR39","doi-asserted-by":"publisher","first-page":"e000103","DOI":"10.1161\/JAHA.113.000103","volume":"2","author":"H Kusunoki","year":"2013","unstructured":"Kusunoki H, Taniyama Y, Rakugi H, Morishita R . Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorgamma-hepatocyte growth factor pathway independent of angiotensin II type 1a receptor blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc 2013; 2: e000103.","journal-title":"J Am Heart Assoc"},{"key":"BFhr2015141_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.cardiores.2005.10.002","volume":"69","author":"D Vanhoutte","year":"2006","unstructured":"Vanhoutte D, Schellings M, Pinto Y, Heymans S . Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006; 69: 604\u2013613.","journal-title":"Cardiovasc Res"},{"key":"BFhr2015141_CR41","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1253\/circj.CJ-13-0013","volume":"77","author":"T Anzai","year":"2013","unstructured":"Anzai T . Post-infarction inflammation and left ventricular remodeling: a double-edged sword. Circ J 2013; 77: 580\u2013587.","journal-title":"Circ J"},{"key":"BFhr2015141_CR42","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.yjmcc.2010.12.021","volume":"50","author":"G Vilahur","year":"2011","unstructured":"Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L . Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol 2011; 50: 522\u2013533.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr2015141_CR43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardiores.2006.10.002","volume":"74","author":"M Bujak","year":"2007","unstructured":"Bujak M, Frangogiannis NG . The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74: 184\u2013195.","journal-title":"Cardiovasc Res"},{"key":"BFhr2015141_CR44","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/01.RES.0000130526.20854.fa","volume":"94","author":"M Nian","year":"2004","unstructured":"Nian M, Lee P, Khaper N, Liu P . Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94: 1543\u20131553.","journal-title":"Circ Res"},{"key":"BFhr2015141_CR45","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1097\/HJH.0b013e32834786f0","volume":"29","author":"W Cao","year":"2011","unstructured":"Cao W, Zhou QG, Nie J, Wang GB, Liu Y, Zhou ZM, Hou FF . Albumin overload activates intrarenal renin-angiotensin system through protein kinase C and NADPH oxidase-dependent pathway. J Hypertens 2011; 29: 1411\u20131421.","journal-title":"J Hypertens"},{"key":"BFhr2015141_CR46","doi-asserted-by":"publisher","first-page":"23011","DOI":"10.3390\/ijms141123011","volume":"14","author":"S Rubattu","year":"2013","unstructured":"Rubattu S, Mennuni S, Testa M, Mennuni M, Pierelli G, Pagliaro B, Gabriele E, Coluccia R, Autore C, Volpe M . Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? Int J Mol Sci 2013; 14: 23011\u201323032.","journal-title":"Int J Mol Sci"},{"key":"BFhr2015141_CR47","doi-asserted-by":"publisher","first-page":"H1738","DOI":"10.1152\/ajpheart.00341.2006","volume":"291","author":"J Chen","year":"2006","unstructured":"Chen J, Mehta JL . Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006; 291: H1738\u2013H1745.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFhr2015141_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/CIRCULATIONAHA.114.011079","volume":"131","author":"QD Zhao","year":"2015","unstructured":"Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, Bhandari B, Abboud HE . NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt\/mTOR and NFkappaB signaling pathways. Circulation 2015; 131: 643\u2013655.","journal-title":"Circulation"},{"key":"BFhr2015141_CR49","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1093\/ndt\/gft376","volume":"28","author":"E Cho","year":"2013","unstructured":"Cho E, Kim M, Ko YS, Lee HY, Song M, Kim MG, Kim HK, Cho WY, Jo SK . Role of inflammation in the pathogenesis of cardiorenal syndrome in a rat myocardial infarction model. Nephrol Dial Transplant 2013; 28: 2766\u20132778.","journal-title":"Nephrol Dial Transplant"},{"key":"BFhr2015141_CR50","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1007\/s11033-014-3685-5","volume":"41","author":"Z Dong","year":"2014","unstructured":"Dong Z, Wu P, Li Y, Shen Y, Xin P, Li S, Wang Z, Dai X, Zhu W, Wei M . Myocardial infarction worsens glomerular injury and microalbuminuria in rats with pre-existing renal impairment accompanied by the activation of ER stress and inflammation. Mol Biol Rep 2014; 41: 7911\u20137921.","journal-title":"Mol Biol Rep"},{"key":"BFhr2015141_CR51","doi-asserted-by":"publisher","first-page":"917","DOI":"10.7326\/0003-4819-138-11-200306030-00013","volume":"138","author":"MG Shlipak","year":"2003","unstructured":"Shlipak MG . Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138: 917\u2013924.","journal-title":"Ann Intern Med"},{"key":"BFhr2015141_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.regpep.2009.02.006","volume":"154","author":"T Nishikimi","year":"2009","unstructured":"Nishikimi T, Inaba-Iemura C, Ishimura K, Tadokoro K, Koshikawa S, Ishikawa K, Akimoto K, Hattori Y, Kasai K, Minamino N, Maeda N, Matsuoka H . Natriuretic peptide\/natriuretic peptide receptor-a (NPR-a) system has inhibitory effects in renal fibrosis in mice. Regul Pept 2009; 154: 44\u201353.","journal-title":"Regul Pept"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2015141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015141","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2015141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T18:46:48Z","timestamp":1748717208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2015141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,10]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFhr2015141"],"URL":"https:\/\/doi.org\/10.1038\/hr.2015.141","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,10]]},"assertion":[{"value":"18 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}